Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Rua Bioscience Limited Share Issue/Capital Change 2025

May 14, 2025

66262_rns_2025-05-15_8afcff65-af98-46fd-a5a9-8c535814fff2.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Capital Change Notice

==> picture [78 x 33] intentionally omitted <==

Section 1: Issuer information
Name of issuer Rua Bioscience Limited
NZX ticker code RUA
Class of financial product Ordinary shares
ISIN (If unknown, check on NZX website) NZRUAE0004S1
Currency NZ$
Section 2: Capital change details
Number issued/acquired/redeemed 139,780 warrants
Nominal value (if any) N/A
Issue/acquisition/redemption price per security $0.015
Nature of the payment (for example, cash or other
consideration)
No consideration is payable for
the warrants. Cash
consideration of $0.015 per
share is payable on exercise of
the warrants
Amount paid up (if not in full) Paid in full on exercise of the
warrant
Percentage of total class of Financial Products
issued/acquired/redeemed/ (calculated on the number of
Financial Products of the Class, excluding any Treasury Stock,
in existence)1
Rua currently has 223,648,012
ordinary shares on issue.
This issue of warrants
represents 0.063% of the total
ordinary shares on issue
(being the percentage should
all warrants vest and be
exercised).
For an issue of Convertible Financial Products or Options, the
principal terms of Conversion (for example the Conversion
price and Conversion date and the ranking of the Financial
Product in relation to other Classes of Financial Product) or the
Option (for example, the exercise price and exercise date)
Vesting will occur 12 months
following the
Issue/Commencement Date
after which the warrants are
able to be converted/exercised
to ordinary shares up to the
Maturity Date which is 3 years
following the
Issue/Commencement Date.
Reason for issue/acquisition/redemption and specific authority
for issue/acquisition/redemption/ (the reason for change must
be identified here)
Issue of warrants as per Board
Resolution regarding debt
facility arrangement.
Total number of Financial Products of the Class after the
issue/acquisition/redemption/Conversion (excluding Treasury
Stock) and the total number of Financial Products of the Class
held as Treasury Stock after the issue/acquisition/redemption.
Total ordinary shares on issue:
223,648,012 ordinary shares
Total warrants on issue:
139,780 warrants

1 The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

In the case of an acquisition of shares, whether those shares
are to be held as treasury stock
N/A
Specific authority for the issue, acquisition, or redemption,
including a reference to the rule pursuant to which the issue,
acquisition, or redemption is made
Board resolution dated 14 May
2025 and Listing Rule 4.5.1
Terms or details of the issue, acquisition, or redemption (for
example: restrictions, escrow arrangements)
The warrants are issued as
part of a Debt Facility
arrangement.
Vesting will occur 12 months
following the
Issue/Commencement Date
after which the warrants are
able to be converted to
ordinary shares up to the
Maturity Date which is 3 years
following the
Issue/Commencement Date.
New ordinary shares issued
upon exercise of the warrants
will rank equally in all respects
with the ordinary shares
already on issue.
Date of issue/acquisition/redemption 14/05/2025
Section 3: Authority for this announcement and contact person
Name of person authorised to make this announcement Paul Naske
Contact person for this announcement Paul Naske
Contact phone number 021 445 154
Contact email address [email protected]
Date of release through MAP 14/05/2025